

Expanding the TRIPS Waiver Is Unnecessary and Harmful

September 2022



Key Takeaways



Biopharmaceutical manufacturers are already sharing their IP and remain committed to providing timely, equitable global access to safe and effective COVID-19 vaccines and treatments – Supply far exceeds demand



Giving away American IP on treatments to foreign countries will outsource U.S. manufacturing jobs and weaken U.S. biopharmaceutical leadership




Expanding the waiver to include COVID-19 treatments will undercut U.S. innovation and jeopardize our ability to fight COVID-19 and other conditions

Global Partnerships Are Fueling Production and Patient Access to COVID-19 Vaccines and Treatments


The Supply of COVID-19 Treatments Far Exceeds Demand

Governments and NGOs Purchased 80 Million Courses of COVID-19 Treatments for 2022 but Have Administered Only 18 Million Courses So Far



Industry Licensing Agreements Made Possible by Intellectual Property Are Meeting Demand for COVID-19 Treatments

143 COVID-19 Treatment Licensing Agreements Span 32 Nations



Bangladesh



Belgium



Brazil



Canada



China



Dominican Republic



Egypt



Jordan



Korea



France



Germany



India



Indonesia



Ireland



Israel



Italy



Japan



Jordan



Kenya



Mexico




Pakistan



Paraguay



Portugal



Russia



Serbia



Singapore



South Africa



Switzerland



Ukraine



United Kingdom



United States




Vietnam

U.S. Economic Impact of the Development and Manufacturing of COVID-19 Vaccines and Treatments

Over 400,000 U.S. Jobs Are Supported by the Development and Manufacturing of COVID-19 Vaccines and Treatments

Expanding the TRIPS Waiver Would Harm American Workers


Total Jobs Directly and Indirectly Supported by Development and Manufacturing




Total Economic Impact Occurs Across Several Sectors

60% of U.S. Jobs Supported by COVID-19 Vaccines and Treatments Are Outside the Biopharmaceutical Industry

Composition of Jobs by Sector




Number of Jobs by Sector (in thousands)



Almost 90% of COVID-19 Clinical Trial Costs in the United States Are for Treatments

There Have Been Over 1,200 U.S. Clinical Trials for COVID-19 Treatments

**U.S. COVID-19 Clinical Trial Costs:
\$24 Billion to Date**




- Over **\$24 billion** has been spent on clinical trials for COVID-19 vaccines and treatments in the United States – supporting about **100,000 U.S. jobs**
- Another **\$80 billion** will be spent in the United States over the next several years if vaccines and treatments in the pipeline continue through clinical trials to approval – supporting approximately **110,000 U.S. jobs** annually

Exports Drive Over 55% of COVID-19 Product Manufacturing in the United States

U.S. Exports of Biopharmaceutical Products Have Surged to Highest Levels on Record

**U.S. Biopharmaceutical Exports
from 2012 to Q2 2022**




- Over **300,000 U.S. jobs** are supported by the surge in U.S. biopharmaceutical manufacturing for COVID-19 vaccines and treatments
- **55%** of these jobs are supported by **U.S. exports** of biopharmaceutical products
- **U.S. exports** of biopharmaceutical products **increased over 60%** after the U.S. amended COVID-19 vaccine contracts in mid-2021

U.S. Scientific Research and Manufacturing Jobs Have Increased by More than 180,000 Since 2019

Scientific Research Jobs for New Medicines Create Manufacturing Jobs


U.S. Scientific Research Jobs (in thousands)

**+121,000 jobs
since 2019**



U.S. Biopharmaceutical Manufacturing Jobs (in thousands)


**+63,000 jobs
since 2019**



New Biopharmaceutical Industry Investment in the United States Increased 70% in 2021 – Half of the Global Total


Expanding the TRIPS Waiver Would Put at Risk U.S. Biopharmaceutical Leadership

New Biopharmaceutical Industry R&D and Manufacturing Facility Investment by Destination Country (in billions of U.S. dollars)



Expanding the TRIPS Waiver Would Undercut U.S. Medical Innovation and Our Ability to Fight Future Pandemics


Nearly 2,000 Clinical Trials Underway Across the Globe to Fight COVID-19



Industry Has a Diverse Research and Development Pipeline

Ongoing Clinical Trials Represent Many Approaches for Preventing and Treating COVID-19

Number of Clinical Trials Testing Different Types of COVID-19 Vaccines and Treatments




Hundreds of Clinical Trials are Testing 176 Unique Investigational Treatments from PhRMA Member Companies



Most Treatments in the COVID-19 Pipeline Are Also Being Developed for Other Conditions

Expanding the TRIPS Waiver Would Put at Risk the Pipeline for Many Conditions

COVID-19 Treatments in Development



370 U.S. Clinical Trials Are Testing COVID-19 Treatments for Other Conditions

Oncology Accounts for 42% of these Clinical Trials

